NDA 216665 · Soleno
Vykat Xr
Diazoxide Choline · Oral
Breakthrough therapyPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Mar 26, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Mar 26, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
13
5 Phase 3, 0 recruiting
FAERS reports
690
134 serious, 7 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 26, 2025.
VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). ( 1 )
Mechanism: The exact mechanism of action of diazoxide choline in the treatment of hyperphagia in patients 4 years of age and older with Prader-Willi syndrome (PWS) is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 26, 2025 Original approval · Type 2 - New Active Ingredient · priority review Breakthrough therapyOrphanLabelMedication GuideLetter
3 products under this application
- VYKAT XR · DIAZOXIDE CHOLINE 75MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- VYKAT XR · DIAZOXIDE CHOLINE 150MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- VYKAT XR · DIAZOXIDE CHOLINE 25MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Diazoxide Choline" as an intervention, any sponsor and status, largest first.
- A Study of Diazoxide Choline in Patients With Prader-Willi SyndromePivotal-lookingCompleted
Soleno Therapeutics, Inc.Industry
NCT03440814 · 127 participants · Start May 9, 2018 · Primary completion May 1, 2020
Drug: DCCR; Placebo for DCCR · For: Prader-Willi Syndrome
Sites: Orange, California; Palo Alto, California; San Diego, California · 29 sites in all
- Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal PeriodPivotal-lookingCompleted
Soleno Therapeutics, Inc.Industry
NCT03714373 · 115 participants · Start Oct 1, 2018 · Primary completion Aug 17, 2023
Drug: DCCR; DCCR and 1 more · For: Prader-Willi Syndrome
Sites: Orange, California; Palo Alto, California; San Diego, California · 28 sites in all
Essentialis, Inc.Industry
NCT00696475 · 80 participants (planned) · Start Jun 2008 · Primary completion Jan 2009
Drug: Diazoxide choline; Diazoxide choline and 2 more · For: Hypertriglyceridemia
Sites: Los Angeles, California; Jacksonville, Florida; Miami Gardens, Florida · 12 sites in all
- Open-Label Extension Study of DCCR in Patients With Prader-Willi SyndromePivotal-lookingCompleted
Soleno Therapeutics, Inc.Industry
NCT05701774 · 77 participants · Start Jan 31, 2023 · Primary completion Jan 12, 2026
Drug: DCCR · For: Prader-Willi Syndrome
Sites: Orange, California; Palo Alto, California; San Diego, California · 22 sites in all
Essentialis, Inc.Industry
NCT01211847 · 44 participants · Start Oct 2010 · Primary completion Sep 2011
Drug: Diazoxide Choline Controlled-Release Tablet; Placebo · For: Hypertriglyceridemia; Dyslipidemia
Essentialis, Inc.Industry
NCT02034071 · 13 participants · Start Apr 2014 · Primary completion May 2015
Drug: DCCR; Placebo · For: Prader-Willi Syndrome
Sites: Orange, California
Essentialis, Inc.Industry
NCT00688857 · 12 participants (planned) · Start May 2008 · Primary completion Jun 2008
Drug: Diazoxide choline; Diazoxide choline · For: Hypertriglyceridemia
Sites: Fargo, North Dakota
Essentialis, Inc.Industry
NCT01211860 · 9 participants · Start Oct 2010 · Primary completion Nov 2010
Drug: Diazoxide Choline Controlled-Release Tablet · For: Hypertriglyceridmia
Sites: Fargo, North Dakota
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- oedema peripheral135
- peripheral swelling98
- weight increased97
- drug ineffective95
- blood glucose increased84
- fluid retention75
- oedema59
- hair growth abnormal48
- hyperglycaemia45
- hyperphagia45
- abnormal behaviour44
- hypertrichosis37
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 172 |
| 2026 | 518 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial.
Miller JL, Gevers E, Bridges N, et al. · J Clin Endocrinol Metab 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Diazoxide Choline Extended-release Tablets in Prader-Willi Syndrome: A Randomized, Double-blind, Withdrawal Period Study.
Miller JL, Bridges N, Felner EI, et al. · J Clin Endocrinol Metab 2026 · Randomized Controlled Trial
- A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome.
Kimonis V, Surampalli A, Wencel M, et al. · PLoS One 2019 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: Soleno
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.